Immutep Eftilagimod Alfa MHC Class II Activator Heading to ASCO 2026 with Lymphocyte Activation + Survival Outcomes Data in Metastatic Cancer
Immutep announced April 22 that an abstract for its lead asset eftilagimod alfa — a soluble LAG-3 protein that activates antigen-presenting cells via MHC class II — has been accepted for poster presentation at ASCO 2026 (May 29–June 2, Chicago). The abstract, titled 'Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients,' adds a non-checkpoint immunotherapy modality to the ASCO 2026 peptide-and-immuno slate alongside Bicycle Therapeutics' Duravelo-2, BriaCell's Bria-IMT, BioVaxys's MVP-S, and Greenwich LifeSciences' GP2 program.